Last week’s ISMPP-U webinar ‘Open Access and Medical Publishing’, developed by the Medical Publishing Insights & Practices (MPIP) initiative and Open Pharma and moderated by LaVerne Mooney (Pfizer) and Chris Winchester (Oxford PharmaGenesis), aimed to define the key elements of open access policies, to provide insight into the changing publishing environment and to understand the perspectives of non-commercial and commercial stakeholders on open access publishing.
MPIP launches new open access toolkit
A new reference site from Medical Publishing Insights and Practices (MPIP) aims to educate its users on the ins and outs of open access as part of its commitment to improving research transparency in pharma. With open access everywhere nowadays, it is very important to know what it is and how it works. However, this … Continue reading MPIP launches new open access toolkit
Weekly digest: what’s happening in open science?
Featuring how libraries can support Plan S implementation, the Incentivization Blueprint encouraging funders to align with the principles of open research, and the effect on citation performance of a journal becoming open access.
Weekly digest: what’s happening in open science?
Featuring pharma taking the lead on sharing clinical trial results, where preprints end up, and the identity of peer reviewers.
Weekly digest: what’s happening in Open Science?
Featuring the release of the Foundations for Open Scholarship Strategy Development document, the addition of citation data to Altmetric, the launch of Participation Reports by Crossref, and The Francis Crick Institute’s commitment to open access and preprints.
Weekly digest: what’s happening in Open Science?
Featuring the launch of cloud-based technology that enables one-click access to research articles, the new supplement for publishing negative results, and the first publisher-owned open research platform.
Perspectives on open access from the 14th Annual Meeting of ISMPP
Open access publishing of medical research is increasingly prevalent, but open access terminology is varied and confusing. Gold, green, bronze, hybrid, CC BY, CC BY-NC – what does it all mean, and what is the best type of open access? At the 14th Annual Meeting of the International Society of Medical Publication Professionals, a panel of stakeholders in medical publications met to discuss open access from different perspectives.
Time to embrace change in medical publishing?
At this year’s ISMPP European meeting, a panel of Open Pharma members discussed open access, preprints and post-publication peer review, and the possibility of utilizing these tools to make the publishing of pharmaceutical research faster and more transparent.
Open Pharma at ISMPP Europe 2018
Here’s our summary of key points from selected presentations at the 2018 European meeting of ISMPP.
Open Pharma: a publisher’s perspective
We aimed to gain insight into the publishing industry’s perspective on new innovations in the field, as their collaboration will be key to implementing changes.